This study is designed to test the effects of vigabatrin (gamma-vinyl-GABA) an experimental
drug used for the treatment of epilepsy. The study will use positron emission tomography
(PET scan) to detect areas of the brain receiving increased blood flow and using increased
amounts of glucose. Increases in blood flow and glucose use are good indicators of brain
Researchers are interested in determining the effects of Vigabatrin on brain blood flow and
This double-blind placebo-controlled parallel design protocol will investigate the effects
of gamma-vinyl-GABA (vigabatrin--GVG) an experimental antiepileptic drug, on cerebral
glucose metabolism (LCMRglc), blood flow (CBF), and seizure frequency, in patients with
uncontrolled complex partial (CPS) and secondary generalized seizures (GTCS). Positron
Emission Tomography (PET) will be used to measure CBF and LCMRglc.
Ability to tolerate tegretol monotherapy.
No systemic illness requiring drug therapy.
No illness that might be made worse by vigabatrin.